Top Suppliers:I want be here
Related CAS#:
142340-99-6 1215101-42-0
323201-06-5 1346604-40-7
1875153-79-9 1346603-65-3
1190021-70-5 106941-25-7
441785-26-8 1066-40-6
2034238-03-2 2034483-41-3
2034401-79-9 2034329-25-2
2034238-12-3 2034401-91-5
2034483-44-6 2034329-31-0
2034401-98-2 2034329-41-2

142340-99-6

142340-99-6 structure
142340-99-6 structure
  • Name: Adefovir Dipivoxil
  • Chemical Name: Adefovir dipivoxil
  • CAS Number: 142340-99-6
  • Molecular Formula: C20H32N5O8P
  • Molecular Weight: 501.470
  • Catalog: API Synthetic anti-infective drugs Antiviral drugs
  • Create Date: 2018-02-07 08:00:00
  • Modify Date: 2024-01-02 06:37:33
  • Adefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body.Target: NRTIs; HBVAdefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body. Adefovir Dipivoxil is used for treatment of hepatitis B and herpes simplex virus infection [1-3]. Adefovir Dipivoxil is approved for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (primarily ALT) or histologically active disease. Adefovir Dipivoxil is a failed treatment for HIV[3, 4].
Name Adefovir dipivoxil
Synonyms 9-[2-[Bis(pivaloyloxymethoxy)phosphorylmethoxy]ethyl]adenine
BIS POM PMEA
ADEFOVIR PIVOXIL
Adefovir Dipivoxil
9-(2[bis(Pivaloyloxymethoxy)phosphorylmethoxy]ethyl)adenine
Hepsera
ADEFOVIR DIPVOXIL
Preveon
MFCD00869897
EINECS 200-001-8
ADEFOVIR DIPIVOLIX
Adefovir Dipivoxyl
Adefovir Dipivoxi
Adefovir Dipivoxl
Adefovir Impurity 3
Description Adefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body.Target: NRTIs; HBVAdefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body. Adefovir Dipivoxil is used for treatment of hepatitis B and herpes simplex virus infection [1-3]. Adefovir Dipivoxil is approved for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (primarily ALT) or histologically active disease. Adefovir Dipivoxil is a failed treatment for HIV[3, 4].
Related Catalog
References

[1]. Marcellin, P., et al., Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 2003. 348(9): p. 808-16.

[2]. Manolakopoulos, S., et al., Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther, 2008. 27(3): p. 266-73.

[3]. Committee, A.I.S., A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. HIV Med, 2002. 3(4): p. 229-38.

[4]. Fisher, E.J., et al., The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS, 2001. 15(13): p. 1695-700.
Density 1.4±0.1 g/cm3
Boiling Point 641.0±65.0 °C at 760 mmHg
Melting Point 98-102ºC
Molecular Formula C20H32N5O8P
Molecular Weight 501.470
Flash Point 341.5±34.3 °C
Exact Mass 501.198853
PSA 176.79000
LogP 2.45
Vapour Pressure 0.0±1.9 mmHg at 25°C
Index of Refraction 1.569
Storage condition −20°C
Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H302-H312-H332
Precautionary Statements P280
Personal Protective Equipment dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes Xi
Risk Phrases R20/21/22
Safety Phrases 36/37
RIDADR NONH for all modes of transport
18997-19-8 structure

18997-19-8

106941-25-7 structure

106941-25-7

~75%

142340-99-6 structure

142340-99-6

Literature: WO2010/110506 A1, ; Page/Page column 7 ;
922494-99-3 structure

922494-99-3

~%

142340-99-6 structure

142340-99-6

Literature: WO2007/13085 A1, ; Page/Page column 10-11 ;
18997-19-8 structure

18997-19-8

116384-53-3 structure

116384-53-3

~%

142340-99-6 structure

142340-99-6

Literature: European Journal of Medicinal Chemistry, , vol. 63, p. 869 - 881
18997-19-8 structure

18997-19-8

106941-25-7 structure

106941-25-7

~%

323201-04-3 structure

323201-04-3

142340-99-6 structure

142340-99-6

Literature: EP2330107 A2, ; Page/Page column 6 ;
53064-79-2 structure

53064-79-2

~%

142340-99-6 structure

142340-99-6

Literature: Journal of Medicinal Chemistry, , vol. 39, # 25 p. 4958 - 4965
153235-86-0 structure

153235-86-0

~%

142340-99-6 structure

142340-99-6

Literature: Journal of Medicinal Chemistry, , vol. 39, # 25 p. 4958 - 4965
66224-66-6 structure

66224-66-6

~%

142340-99-6 structure

142340-99-6

Literature: US2012/238753 A1, ;
116384-53-3 structure

116384-53-3

~%

142340-99-6 structure

142340-99-6

Literature: US2012/238753 A1, ;
707-99-3 structure

707-99-3

~%

142340-99-6 structure

142340-99-6

Literature: European Journal of Medicinal Chemistry, , vol. 63, p. 869 - 881

Chemsrc provides CAS#:142340-99-6 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 142340-99-6 | Chemsrc address: https://www.chemsrc.com/en/baike/325061.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved